Research Article
A model for immunological correlates of protection
Abstract
Immunological assays measure characteristics of the immune system, such as antibody levels, specific to certain diseases. High assay values are often associated with protection from disease. A question of interest is how the relationship between assay values and subsequent development of disease should be quantitatively modelled. Existing approaches successfully model the relationship for high assay values, where the probability of developing disease is low. However at low assay values, the probability of developing disease is more closely associated with factors such as disease prevalence rates and an individual's chance of exposure to infection; these are less well captured by existing models. This paper presents a model that accommodates both assay values and factors independent of assay values, enabling protection from disease to be modelled over the whole range of assay values and proposing a method for predicting the efficacy of a vaccine from the assays of vaccinees and non‐vaccinees. Copyright © 2005 John Wiley & Sons, Ltd.
Citing Literature
Number of times cited according to CrossRef: 30
- Andrea Callegaro, Fabian Tibaldi, Assessing correlates of protection in vaccine trials: statistical solutions in the context of high vaccine efficacy, BMC Medical Research Methodology, 10.1186/s12874-019-0687-y, 19, 1, (2019).
- Sylvia Ranjeva, Rahul Subramanian, Vicky J. Fang, Gabriel M. Leung, Dennis K. M. Ip, Ranawaka A. P. M. Perera, J. S. Malik Peiris, Benjamin J. Cowling, Sarah Cobey, Age-specific differences in the dynamics of protective immunity to influenza, Nature Communications, 10.1038/s41467-019-09652-6, 10, 1, (2019).
- Stanley A. Plotkin, Peter Gilbert, Correlates of Protection, Plotkin's Vaccines, 10.1016/B978-0-323-35761-6.00003-1, (35-40.e4), (2018).
- Hsiang-Yu Yuan, Marc Baguelin, Kin O. Kwok, Nimalan Arinaminpathy, Edwin van Leeuwen, Steven Riley, The impact of stratified immunity on the transmission dynamics of influenza, Epidemics, 10.1016/j.epidem.2017.03.003, 20, (84-93), (2017).
- W.E.P. Beyer, A.M. Palache, M. Boulfich, A.D.M.E. Osterhaus, Rationale for two influenza B lineages in seasonal vaccines: A meta-regression study on immunogenicity and controlled field trials, Vaccine, 10.1016/j.vaccine.2017.06.038, 35, 33, (4167-4176), (2017).
- Jorge M. Arevalillo, Marcelo B. Sztein, Karen L. Kotloff, Myron M. Levine, Jakub K. Simon, Identification of immune correlates of protection in Shigella infection by application of machine learning, Journal of Biomedical Informatics, 10.1016/j.jbi.2017.08.005, 74, (1-9), (2017).
- Wenbo Zhu, Pengfei Jin, Jing-Xin Li, Feng-Cai Zhu, Pei Liu, Correlates of protection for inactivated enterovirus 71 vaccine: the analysis of immunological surrogate endpoints, Expert Review of Vaccines, 10.1080/14760584.2017.1335603, 16, 9, (945-949), (2017).
- Pengfei Jin, Jingxin Li, Xuefeng Zhang, Fangyue Meng, Yang Zhou, Xuejun Yao, Zhengkai Gan, Fengcai Zhu, Validation and evaluation of serological correlates of protection for inactivated enterovirus 71 vaccine in children aged 6-35 months, Human Vaccines & Immunotherapeutics, 10.1080/21645515.2015.1118595, 12, 4, (916-921), (2016).
- Andrew J. Dunning, Carlos A. DiazGranados, Timothy Voloshen, Branda Hu, Victoria A. Landolfi, H. Keipp Talbot, Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial, Clinical and Vaccine Immunology, 10.1128/CVI.00604-15, 23, 3, (228-235), (2016).
- Carlos A. DiazGranados, William Saway, James Gouaux, Mira Baron, Jeffrey Baker, Martine Denis, Emilia Jordanov, Victoria Landolfi, Eddy Yau, Safety and immunogenicity of high-dose trivalent inactivated influenza vaccine in adults 50–64 years of age, Vaccine, 10.1016/j.vaccine.2015.10.131, 33, 51, (7188-7193), (2015).
- Paul S. Wikramaratna, Andrew Rambaut, Relationship between haemagglutination inhibition titre and immunity to influenza in ferrets, Vaccine, 10.1016/j.vaccine.2015.08.065, 33, 41, (5380-5385), (2015).
- Andrew J. Dunning, Jennifer Kensler, Laurent Coudeville, Fabrice Bailleux, Some extensions in continuous models for immunological correlates of protection, BMC Medical Research Methodology, 10.1186/s12874-015-0096-9, 15, 1, (2015).
- Rosemary Markovic Delabre, Nicolas Salez, Magali Lemaitre, Marianne Leruez-Ville, Xavier de Lamballerie, Fabrice Carrat, Antibody persistence and serological protection among seasonal 2007 influenza A(H1N1) infected subjects: Results from the FLUREC cohort study, Vaccine, 10.1016/j.vaccine.2015.09.016, 33, 49, (7015-7021), (2015).
- Anne Benoit, Jiri Beran, Jeanne-Marie Devaster, Meral Esen, Odile Launay, Geert Leroux-Roels, Janet E. McElhaney, Lidia Oostvogels, Gerrit A. van Essen, Manjusha Gaglani, Lisa A. Jackson, Timo Vesikari, Catherine Legrand, Fabian Tibaldi, Bruce L. Innis, Walthère Dewé, Hemagglutination Inhibition Antibody Titers as a Correlate of Protection Against Seasonal A/H3N2 Influenza Disease, Open Forum Infectious Diseases, 10.1093/ofid/ofv067, 2, 2, (2015).
- Juana Angel, A Duncan Steele, Manuel A Franco, Correlates of protection for rotavirus vaccines: Possible alternative trial endpoints, opportunities, and challenges, Human Vaccines & Immunotherapeutics, 10.4161/hv.34361, 10, 12, (3659-3671), (2014).
- Tim K. Tsang, Simon Cauchemez, Ranawaka A. P. M. Perera, Guy Freeman, Vicky J. Fang, Dennis K. M. Ip, Gabriel M. Leung, Joseph Sriyal Malik Peiris, Benjamin J. Cowling, Association Between Antibody Titers and Protection Against Influenza Virus Infection Within Households, The Journal of Infectious Diseases, 10.1093/infdis/jiu186, 210, 5, (684-692), (2014).
- Ivan S. F. Chan, Vaccine, Wiley StatsRef: Statistics Reference Online, 10.1002/9781118445112, (2014).
- Laurent Coudeville, Philippe Andre, Fabrice Bailleux, Françoise Weber, Stanley Plotkin, A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes, Human Vaccines, 10.4161/hv.6.10.12636, 6, 10, (841-848), (2014).
- Claudia Trombetta, Daniele Perini, Stuart Mather, Nigel Temperton, Emanuele Montomoli, Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future, Vaccines, 10.3390/vaccines2040707, 2, 4, (707-734), (2014).
- Daniel Herrera, Olga L. Rojas, Carolina Duarte-Rey, Rubén D. Mantilla, Juana Ángel, Manuel A. Franco, Simultaneous Assessment of Rotavirus-Specific Memory B Cells and Serological Memory after B Cell Depletion Therapy with Rituximab, PLoS ONE, 10.1371/journal.pone.0097087, 9, 5, (e97087), (2014).
- Xuan Chen, Fabrice Bailleux, Kamal Desai, Li Qin, Andrew J Dunning, A threshold method for immunological correlates of protection, BMC Medical Research Methodology, 10.1186/1471-2288-13-29, 13, 1, (2013).
- Katherine ED Giacoletti, Joseph Heyse, Using proportion of similar response to evaluate correlates of protection for vaccine efficacy, Statistical Methods in Medical Research, 10.1177/0962280211416299, 24, 2, (273-286), (2011).
- Steven Black, Uwe Nicolay, Timo Vesikari, Markus Knuf, Giuseppe Del Giudice, Giovanni Della Cioppa, Theodore Tsai, Ralf Clemens, Rino Rappuoli, Hemagglutination Inhibition Antibody Titers as a Correlate of Protection for Inactivated Influenza Vaccines in Children, The Pediatric Infectious Disease Journal, 10.1097/INF.0b013e3182367662, 30, 12, (1081-1085), (2011).
- Xiaoming Li, William W. B. Wang, Guanghan F. Liu, Ivan S. F. Chan, Handling Missing Data in Vaccine Clinical Trials for Immunogenicity and Safety Evaluation, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2011.550111, 21, 2, (294-310), (2011).
- Bohdan Nosyk, Behnam Sharif, Huiying Sun, Curtis Cooper, Aslam H. Anis, The Cost-Effectiveness and Value of Information of Three Influenza Vaccination Dosing Strategies for Individuals with Human Immunodeficiency Virus, PLoS ONE, 10.1371/journal.pone.0027059, 6, 12, (e27059), (2011).
- Laurent Coudeville, Fabrice Bailleux, Benjamin Riche, Françoise Megas, Philippe Andre, René Ecochard, Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model, BMC Medical Research Methodology, 10.1186/1471-2288-10-18, 10, 1, (2010).
- Jozef J.P. Nauta, Walter E.P. Beyer, Albert D.M.E. Osterhaus, On the relationship between mean antibody level, seroprotection and clinical protection from influenza, Biologicals, 10.1016/j.biologicals.2009.02.002, 37, 4, (216-221), (2009).
- Bruce D. Forrest, Michael W. Pride, Andrew J. Dunning, Maria Rosario Z. Capeding, Tawee Chotpitayasunondh, John S. Tam, Ruth Rappaport, John H. Eldridge, William C. Gruber, Correlation of Cellular Immune Responses with Protection against Culture-Confirmed Influenza Virus in Young Children, Clinical and Vaccine Immunology, 10.1128/CVI.00397-07, 15, 7, (1042-1053), (2008).
- Peter B. Gilbert, Li Qin, Steven G. Self, Evaluating a surrogate endpoint at three levels, with application to vaccine development, Statistics in Medicine, 10.1002/sim.3122, 27, 23, (4758-4778), (2007).
- Ivan S. F. Chan, Vaccine, Wiley Encyclopedia of Clinical Trials, 10.1002/9780471462422, (1-7), (2007).
